IBIO logo

iBio Inc

IBIO

Build a strategy around IBIO

Accountable AI Logo

iBio Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-15

Snapshot

  • Cash burn of 17.3M TTM against 28.1M cash = ~19 months runway without additional financing[Free Cash Flow TTM]
  • Revenue of 500K TTM with 10.6M R&D spend - 21x R&D-to-revenue ratio signals pre-commercial stage[Research and Development TTM]
  • P/S ratio of 194x vs industry median 4.1x - valuation entirely dependent on pipeline success[P/S Ratio]

Watch Triggers

  • Cash and Equivalents: Falls below 15MWould signal <12 months runway, forcing near-term dilutive financing
  • Total Revenue TTM: Exceeds 2M quarterlyFirst sign of commercial traction that could justify valuation
  • Issuance of Capital Stock: Exceeds 10M in any quarterLarge equity raise signals runway concerns and dilution risk

Bull Case

Clean balance sheet with 0.06 debt/equity and 44.7M working capital provides flexibility for strategic pivots or partnerships without debt constraints

Debt to EquityWorking Capital

Trading at 1.97x book value with 49.2M tangible book - downside partially protected by asset base if liquidation scenario

P/B RatioTangible Book Value

Bear Case

Revenue declined 40% over 3 years while burning 17.3M annually - business model not generating commercial traction despite R&D investment

Total Revenue 3Y Growth TTMFree Cash Flow TTM

194x P/S assumes massive revenue inflection that contradicts -40% 3Y revenue CAGR trajectory

P/S RatioTotal Revenue 3Y Growth TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
25%

Leverage IBIO's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Cash runway exhaustion within 18-24 months will force dilutive financing or partnership

1-3yhigh
  • FCF burn of -17.3M TTM with only 28.1M cash
  • Revenue 500K insufficient to fund 20.9M operating expenses
  • Historical pattern: 219K stock issuance already in period
Cash 28.1M vs FCF -17.3M = 1.6 years runwayOperating expense 20.9M TTM vs revenue 500K3Y revenue CAGR -39.9% shows declining commercial traction

Valuation Context

Caveats

Public Strategies Rankings

See how iBio Inc ranks across different investment strategies.

Leverage IBIO's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2026 Accountable Finance, Inc. All rights reserved.